Acta Biochimica et Biophysica Sinica · 2023 · 16 citations · 20 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologySignal TransductionCancer Cell SignalingCholesterol MetabolismHepatocellular Carcinoma PharmacotherapyLipid MetabolismMtor Inhibitor TherapyTyrosine Kinase InhibitorsCellular Cholesterol HomeostasisHepatocellular Carcinoma PathogenesisLenvatinib TherapyMtor InhibitionPlasma Cholesterol LevelsSterol Regulatory Element-binding Protein RegulationSterol Regulatory Element-binding ProteinsTyrosine Kinase Inhibitor Therapy
<p indent="0mm">Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular cholesterol levels are associated with tyrosine kinase inhibitor (TKI) efficacy. Here, we show that betulin, a sterol regulatory element-binding protein 2 (SREBP2) inhibitor, markedly enhances the anti-tumor effect of lenvatinib in HCC both <italic>in vitro</italic> and <italic>in vivo</italic>. Our results also show that the combination treatment of lenvatinib and betulin synergistically inhibits the proliferation and clonogenicity of HCC cells. The mRNA and protein expressions of IL-1β are markedly decreased in HCC cells treated with betulin, while the sensitivity of HCC cells to lenvatinib is enhanced. Moreover, we find that the knockdown of <italic>IL-1β</italic> also enhances the efficacy of lenvatinib, and recombinant IL-1β protein rescues cell viability, which is reduced by lenvatinib in HCC cells. Further mechanistic studies indicate that betulin decreases the level of IL-1β in HCC cells by inhibiting the mTOR signaling pathway. Finally, the growth of the tumors in xenograft mouse models subjected to combination treatment is significantly suppressed. In summary, our study reveals that the SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway, which may be a promising therapeutic strategy for patients with HCC.
20
Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
Katrin Düvel, Jessica L. Yecies, Suchithra Menon et al. · Molecular Cell · 2010 · 2K citations · Full text
SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth
Thomas Porstmann, Cláudio R. Santos, B Griffiths et al. · Cell Metabolism · 2008 · 1.4K citations · Full text